ANEBULO PHARMACEUTICALS INC (ANEB)
OTCHealth CareBiotechnologySnapshot 2026-09-04
$0.36-8.05%
Close 2026-09-04 · 1-day change
OTCHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — reduce losses and move toward profitability: metric not reported.
Anebulo Pharmaceuticals is working to recover from losses and delisting risks. The company aims to stabilize its financial condition and regain investor confidence. If it can improve operations and secure listing status, it may rebuild value.
The company is loss-making and recently approved voluntary delisting. Its financial condition remains weak with no clear path to profitability. Continued losses and regulatory issues could erode value further.
The market is selling off sharply, reflecting concerns about the company’s financial health and delisting. There is no clear consensus or guidance priced in, leaving uncertainty about recovery prospects.
Breaks if: no capital access secured and liquidity deteriorates next 12 months
Breaks if: any new delisting notice or regulatory failure next 4 quarters
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a speculative growth investment with a focus on the healthcare sector. The current thesis state is cautious, as the company is experiencing financial losses and has high risk, but it is influenced by broader sector trends.
The market seems to be pricing in significant risk, as indicated by the recent rise in total and market risk. Expectations may be low due to the company's loss-making status and weak recent performance compared to peers.
Fundamentals are likely to remain weak in the near term, given the company's loss-making situation and recent financial results. Management is stable, but the overall performance is below industry standards.
The future trajectory hinges on external factors, such as the performance of sector bellwethers like VRTX, REGN, and ARGX. If these companies continue to perform well, it could provide a lift to ANEB, but any negative shifts could further impact its outlook.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: net losses do not improve or worsen next fiscal year
In the next 1 to 3 years, ANEB's performance will depend heavily on sector dynamics and external economic factors. Not investment advice.